🏛️ Verified NIH Record • Updated 2025-08-15
Akkermansia Muciniphilia and Metabolic Side Effects of ADT (NCT05802121)
🟢 Recruiting Early Phase1 💊 Investigational Drug / Biologic Sponsor: Western University
🩺 Plain-English Summary (8th-Grade Level)
The overriding objectives of this study are: 1. Primary outcomes: 1. To confirm that administration of oral acetate increases the proportion of A. muciniphilia in the stool samples of patients with metastatic, castration-sensitive prostate cancer compared to a standard of care arm. 2. To confirm tolerability and assess for side effects of oral acetate supplementation. 2. Secondary outcomes: 1. To determine if increased counts of A. muciniphilia correlate with improved metabolic parameters and improved bone health.
Who can join: Review the eligibility criteria below.
Location: London Health Sciences Centre - Victoria Hospital — London, Ontario
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- London Health Sciences Centre - Victoria Hospital — London, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.